{"id":25519,"date":"2018-08-07T01:00:00","date_gmt":"2018-08-09T03:36:16","guid":{"rendered":"http:\/\/www.05921.net\/index.php\/2018\/08\/09\/%e5%85%8d%e7%96%ab%e6%a3%80%e6%9f%a5%e7%82%b9%e7%9a%84%e6%95%85%e4%ba%8bpd-1%e5%85%8d%e7%96%ab%e8%81%94%e5%90%88%e7%96%97%e6%b3%95%e5%9c%a8nsclc%e4%b8%ad%e7%9a%84%e7%a0%94%e7%a9%b6%e8%bf%9b%e5%b1%95\/"},"modified":"2018-08-09T11:36:17","modified_gmt":"2018-08-09T03:36:17","slug":"%e5%85%8d%e7%96%ab%e6%a3%80%e6%9f%a5%e7%82%b9%e7%9a%84%e6%95%85%e4%ba%8bpd-1%e5%85%8d%e7%96%ab%e8%81%94%e5%90%88%e7%96%97%e6%b3%95%e5%9c%a8nsclc%e4%b8%ad%e7%9a%84%e7%a0%94%e7%a9%b6%e8%bf%9b%e5%b1%95","status":"publish","type":"post","link":"https:\/\/www.05921.net\/index.php\/25519\/","title":{"rendered":"\u514d\u75ab\u68c0\u67e5\u70b9\u7684\u6545\u4e8b|PD-1\u514d\u75ab\u8054\u5408\u7597\u6cd5\u5728NSCLC\u4e2d\u7684\u7814\u7a76\u8fdb\u5c55"},"content":{"rendered":"
\n

\u514d\u75ab\u68c0\u67e5\u70b9\u662f\u6307\u514d\u75ab\u7cfb\u7edf\u4e2d\u5b58\u5728\u7684\u4e00\u4e9b\u6291\u5236\u6027\u4fe1\u53f7\u901a\u8def\u3002\u673a\u4f53\u5728\u6b63\u5e38\u60c5\u51b5\u4e0b\uff0c\u514d\u75ab\u68c0\u67e5\u70b9\u53ef\u4ee5\u901a\u8fc7\u8c03\u8282\u81ea\u8eab\u514d\u75ab\u53cd\u5e94\u7684\u5f3a\u5ea6\u6765\u7ef4\u6301\u514d\u75ab\u8010\u53d7\uff0c\u7136\u800c\u673a\u4f53\u5728\u53d7\u5230\u80bf\u7624\u4fb5\u88ad\u65f6\uff0c\u514d\u75ab\u68c0\u67e5\u70b9\u7684\u6fc0\u6d3b\u53ef\u6291\u5236\u81ea\u8eab\u514d\u75ab\uff0c\u6709\u5229\u4e8e\u80bf\u7624\u7ec6\u80de\u7684\u751f\u957f\u548c\u9003\u9038\u3002<\/span>PD-1\u662f\u4e00\u79cd\u91cd\u8981\u7684\u514d\u75ab\u68c0\u67e5\u70b9\uff0c\u4ee5PD-1\u4e3a\u9776\u70b9\u7684\u514d\u75ab\u8c03\u8282\u5bf9\u6297\u80bf\u7624\u3001\u6297\u611f\u67d3\u3001\u6297\u81ea\u8eab\u514d\u75ab\u6027\u75be\u75c5\u53ca\u5668\u5b98\u79fb\u690d\u5b58\u6d3b\u7b49\u5747\u6709\u91cd\u8981\u7684\u610f\u4e49\u3002\u5176\u914d\u4f53PD-L1\u4e5f\u53ef\u4f5c\u4e3a\u9776\u70b9\uff0c\u76f8\u5e94\u7684\u6297\u4f53\u4e5f\u53ef\u4ee5\u8d77\u5230\u76f8\u540c\u7684\u4f5c\u7528\u3002PD-1\u548cPD-L1\u7ed3\u5408\u542f\u52a8T\u7ec6\u80de\u7684\u7a0b\u5e8f\u6027\u6b7b\u4ea1\uff0c\u4f7f\u80bf\u7624\u7ec6\u80de\u83b7\u5f97\u514d\u75ab\u9003\u9038\u3002<\/span><\/span><\/p>\n

PD -1\u6291\u5236\u5242\u662f\u4e00\u7c7b\u514d\u75ab\u6cbb\u7597\u7684\u65b0\u836f\uff0c\u662f\u8fd1\u5e74\u6765\u5168\u7403\u6700\u70ed\u95e8\u7684\u80bf\u7624\u836f\u7269\u7814\u53d1\u65b9\u5411\u4e4b\u4e00\u3002\u636e\u5fb7\u610f\u5fd7\u94f6\u884c\u9884\u6d4b\uff0c<\/span>PD-1\/PD-L1\u6291\u5236\u5242\u5728\u4e2d\u56fd\u7684\u5e02\u573a\u603b\u91cf\uff08\u6cbb\u7597\u6240\u6709\u764c\u75c7\uff09\u5728<\/span>2025<\/span>\u5e74\u5c06\u8fbe\u5230<\/span>250<\/span>\u4ebf\u5143\u3002\u9762\u5bf9\u5982\u6b64\u5927\u7684\u5e02\u573a\uff0c\u56fd\u5185\u73b0\u5728\u6709\u8fd1<\/span>20<\/span>\u5bb6\u4f01\u4e1a\u6d89\u53ca<\/span>PD-1\/PD-L1<\/span>\u9776\u70b9\u7684\u836f\u7269\u7814\u7a76\uff0c\u5176\u4e2d<\/span>PD-1<\/span>\u5355\u6297\u836f<\/span>11<\/span>\u79cd\uff0c<\/span>PD-L1<\/span>\u5355\u6297\u836f<\/span>5<\/span>\u79cd\uff0c\u7ade\u4e89\u5f02\u5e38\u6fc0\u70c8\u3002<\/span><\/span><\/p>\n

PD-1\u836f\u7269\u6700\u521d\u7528\u6765\u6cbb\u7597\u9ed1\u8272\u7d20\u7624\uff0c\u540e\u6765\u53d1\u5c55\u6210\u5e7f\u8c31\u6297\u764c\u836f\uff0c\u5305\u62ec\u7528\u6765\u6cbb\u7597\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\uff08<\/span>NSCLC<\/span>\uff09\u3002\u5c3d\u7ba1\u514d\u75ab\u7597\u6cd5\u5728<\/span>NSCLC<\/span>\u6cbb\u7597\u4e2d\u53d6\u5f97\u4e86\u4e0d\u5c0f\u7684\u6210\u529f\uff0c\u4f46\u662f\u53ea\u6709\u4e00\u5c0f\u90e8\u5206\u75c5\u4eba\u5bf9\u8fd9\u79cd\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242\u8868\u73b0\u51fa\u4e86\u6301\u4e45\u7684\u54cd\u5e94\u3002\u56e0\u6b64\uff0c\u5229\u7528\u4e0d\u540c\u836f\u7269\u7684\u534f\u540c\u589e\u6548\u4f5c\u7528\u63d0\u9ad8\u54cd\u5e94\u7387\u5df2\u7ecf\u6210\u4e86\u884c\u4e1a\u8d8b\u52bf\u548c\u70ed\u70b9\u3002<\/span><\/span><\/p>\n

\u672c\u6587\u5c06\u5c31<\/span>PD-1\u514d\u75ab\u8054\u5408\u7597\u6cd5\u5728<\/span>NSCLC<\/span>\u4e2d\u7684\u5e94\u7528\u5c55\u5f00\u8ba8\u8bba\u3002<\/span><\/span><\/p>\n

\n
\n
\n
\n

PD-1\u548cCTLA4<\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\u524d\u671f\u7814\u7a76\u53d1\u73b0\uff0c<\/span>PD-1\u548c<\/span>CTLA4<\/span>\u53ef\u901a\u8fc7\u5185\u5728\u7684\u5408\u4f5c\u9014\u5f84\u6291\u5236<\/span>T<\/span>\u7ec6\u80de\u6d3b\u6027\uff0c <\/span>PD-1<\/span>\u548c<\/span>CTLA4<\/span>\u8054\u5408\u7597\u6cd5\u987a\u52bf\u800c\u751f\u3002<\/span>CD28<\/span>\uff08<\/span>T<\/span>\u7ec6\u80de\u8868\u8fbe\u7684\u86cb\u767d\uff0c\u53c2\u4e0e<\/span>T<\/span>\u7ec6\u80de\u6d3b\u52a8\uff09\u548c<\/span>CTLA4<\/span>\u7ade\u4e89\u7ed3\u5408<\/span>CD80\/CD86<\/span>\u53d7\u4f53\uff0c\u8fd9\u4e9b\u53d7\u4f53\u4e0e<\/span>CTLA4<\/span>\u7ed3\u5408\u540e\uff0c\u5bfc\u81f4<\/span>T<\/span>\u7ec6\u80de\u6d3b\u6027\u6fc0\u6d3b\u6240\u9700\u7684<\/span>CD28<\/span>\u5171\u523a\u6fc0\u4fe1\u53f7\u53d7\u5230\u6291\u5236\uff0c\u9274\u4e8e<\/span>PD-1<\/span>\u548c<\/span>PD-L1<\/span>\u4e5f\u53ef\u4ee5\u6291\u5236<\/span>T<\/span>\u7ec6\u80de\u6d3b\u6027\u548c\u6bd2\u6027\uff0c\u6240\u4ee5\uff0c<\/span>PD-1\/PD-L1<\/span>\u548c<\/span>CTLA4<\/span>\u6291\u5236\u5242\u7ed3\u5408\uff0c\u53ef\u4ee5\u663e\u8457\u63d0\u9ad8\u80bf\u7624\u75c5\u4eba\u7684<\/span><\/span>OR\uff08\u5ba2\u89c2\u7f13\u89e3\u7387\uff09\u3002<\/span><\/span><\/span><\/p>\n

\u53cc\u68c0\u67e5\u70b9\u6291\u5236\u5242\u5728\u9ed1\u8272\u7d20\u7624\u75c5\u4eba\u4e2d\u5f97\u5230\u4e86\u63a8\u5e7f\u5e94\u7528\uff0c\u8fd1\u671f\u4e34\u5e8a\u8bd5\u9a8c\u4e5f\u5c06\u6269\u5c55\u5230<\/span>NSCLC\u3002<\/span>Gubens<\/span>\u7b49\u5c06\u6297<\/span>PD-1<\/span>\u6297\u4f53\uff08<\/span>pembrolizumab<\/span>\uff09\u548c<\/span>CTLA4<\/span>\u6291\u5236\u5242\uff08<\/span>ipilimumab<\/span>\uff09\u8054\u5408\u4e8c\u7ebf\u6cbb\u7597<\/span>NSCLC<\/span>\uff0c\u8ddf\u8e2a<\/span>51<\/span>\u4f4d\u75c5\u4eba\u7684<\/span>7<\/span>\u6708\u4e2d\u4f4d\u751f\u5b58\u671f\uff0c<\/span>ORR<\/span>\uff08\u603b\u4f53\u5ba2\u89c2\u7f13\u89e3\u7387\uff09\u8fbe\u5230<\/span>24%<\/span>\uff0c<\/span>2<\/span>\u4f4d\u5b8c\u5168\u7f13\u89e3\uff0c<\/span>9<\/span>\u4f4d\u90e8\u5206\u7f13\u89e3\u3002\u53e6\u5916\uff0c<\/span>40%<\/span>\u75c5\u4eba\u75c5\u60c5\u7a33\u5b9a\uff0c<\/span>18%<\/span>\u75c5\u60c5\u8fdb\u5c55\u3002\u4e2d\u4f4d<\/span>PFS<\/span>\uff08\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff09<\/span>6<\/span>\u4e2a\u6708\uff0c\u603b\u751f\u5b58\u671f<\/span>17<\/span>\u4e2a\u6708\u3002\u7136\u800c\uff0c<\/span>67%<\/span>\u7684\u75c5\u4eba\u51fa\u73b0\u4e86\u6cbb\u7597\u76f8\u5173\u7684\u526f\u4f5c\u7528\uff0c<\/span>11<\/span>\u4f4d\uff08<\/span>24%<\/span>\uff09\u75c5\u4eba\u53d1\u751f<\/span>3-5<\/span>\u7ea7\u6bd2\u6027\u3002<\/span><\/span><\/p>\n

Antonia\u7b49\u4f7f\u7528\u591a\u4e2d\u5fc3\u3001\u975e\u968f\u673a\u3001\u516c\u5f00\u6807\u8bb0\u7684\u65b9\u6cd5\u8bc4\u4f30\u4e86\u6297<\/span>PD-L1<\/span>\u6291\u5236\u5242<\/span>(durvalumab<\/span>)\u548c\u6297<\/span>CTLA4\u6291\u5236\u5242<\/span>(tremelimumab<\/span>)\u7684\u8054\u5408\u7597\u6cd5\u5728<\/span>NSCLC\u7684<\/span>\u2160b\u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u6548\u679c\u3002\u8be5\u9879\u7814\u7a76\u62db\u52df\u4e86\u5242\u91cf\u9012\u589e\u671f\u7684<\/span>102<\/span>\u4f4d\u75c5\u4eba\uff0c\u800c\u4e14\u5141\u8bb8\u75c5\u4eba\u6709\u975e<\/span>PD-L1<\/span>\u8868\u8fbe\u3002\u6700\u5927\u5242\u91cf\u589e\u52a0\u5230\u6bcf<\/span>4<\/span>\u5468<\/span>20mg\/kg<\/span>\u7684<\/span>durvalumab<\/span>\u548c<\/span>3mg\/kg<\/span>\u7684<\/span>tremelimumab<\/span>\u3002\u5728\u8fd9<\/span>102<\/span>\u4f4d\u75c5\u4eba\u4e2d\uff0c<\/span>82<\/span>\u4f4d\uff08<\/span>80%<\/span>\uff09\u6709\u514d\u75ab\u76f8\u5173\u4e0d\u826f\u53cd\u5e94\uff08\u5927\u90e8\u5206\u662f\u8179\u6cfb\u3001\u75b2\u4e4f\u548c\u7619\u75d2\uff09\uff0c<\/span>29<\/span>\u4f4d\uff08<\/span>28%<\/span>\uff09\u75c5\u4eba\u7531\u6b64\u8981\u6c42\u9000\u51fa\u4e34\u5e8a\u8bd5\u9a8c\uff0c<\/span>37<\/span>\u4f4d\uff08<\/span>36%<\/span>\uff09\u75c5\u4eba\u53d1\u751f\u4e86\u4e25\u91cd\u4e0d\u826f\u53cd\u5e94\u3002\u5728\u8fd9\u9879\u7814\u7a76\u4e2d\uff0c <\/span>22<\/span>\u4f8b\u6b7b\u4ea1\uff0c\u5176\u4e2d<\/span>3<\/span>\u4f8b\u4e0e\u8fd9\u79cd\u6cbb\u7597\u65b9\u6cd5\u6709\u5173\u3002\u8ddf\u8e2a<\/span>24<\/span>\u5468\u540e\uff0c<\/span>63<\/span>\u4f4d\u75c5\u4eba\u6709\u4e86\u66f4\u5927\u7684\u4e34\u5e8a\u53cd\u5e94\uff0c<\/span>11<\/span>\u4f4d\u75c5\u4eba\u6709\u4e86\u5ba2\u89c2\u54cd\u5e94\uff0c<\/span>18<\/span>\u4f4d\u75c5\u4eba\u75be\u75c5\u7a33\u5b9a\u3002\u5728<\/span>11<\/span>\u4f4d\u5ba2\u89c2\u54cd\u5e94\u7684\u75c5\u4eba\u4e2d\uff0c\u54cd\u5e94\u7684\u4e2d\u4f4d\u65f6\u95f4\u662f<\/span>7.1<\/span>\u5468\uff0c\u6ca1\u6709\u8fbe\u5230\u4e2d\u4f4d\u7f13\u89e3\u671f\u3002\u5728\u8bc4\u4f30\u7684\u540c\u65f6\uff0c<\/span>11<\/span>\u4f4d\u75c5\u4eba\u4e2d\u7684<\/span>9<\/span>\u4f4d\u7ee7\u7eed\u8fdb\u884c\u4e34\u5e8a\u8bd5\u9a8c\u3002\u6309\u7167\u9884\u671f\u5242\u91cf\uff0c\u6bcf<\/span>4<\/span>\u5468\u7ed9\u836f\u91cf\u662f<\/span>20mg\/kg<\/span>\u7684<\/span>durvalumab<\/span>\u548c<\/span>1mg\/kg<\/span>\u7684<\/span>tremelimumab<\/span>\u3002\u6709\u8da3\u7684\u662f\uff0c\u975e<\/span>PD-L1<\/span>\u80bf\u7624\u75c5\u4eba\u7ea6\u5360\u6bd4<\/span>5%<\/span>\uff0c\u4ed6\u4eec\u5374\u51fa\u73b0\u4e86\u5ba2\u89c2\u54cd\u5e94\u3002\u8fd9\u9884\u793a\u7740\uff0c<\/span>PD-L1<\/span>\u8868\u8fbe\u5e76\u4e0d\u8868\u793a\u5bf9<\/span>durvalumab<\/span>\u548c<\/span>tremelimumab<\/span>\u7684\u7ec4\u5408\u6bd4\u5355\u72ec\u7684<\/span>durvalumab<\/span>\u66f4\u6709\u6548\u3002<\/span><\/span><\/p>\n

Hellmann\u7b49\u7814\u7a76\u53d1\u73b0\uff0c\u8054\u5408<\/span>nivolumab<\/span>\u548c<\/span>ipilimumab<\/span>\u5728\u4e00\u7ebf\u6cbb\u7597\u4e2d\u6709\u79ef\u6781\u4f5c\u7528\uff0c\u800c\u4e14\u6709\u6301\u4e45\u7684\u54cd\u5e94\u3002\u5355\u72ec\u4f7f\u7528<\/span>nivolumab<\/span>\u7684<\/span>\u2162\u671f\u4e34\u5e8a\u8bd5\u9a8c\u6b63\u5728\u7ee7\u7eed\u8fdb\u884c\uff0c\u540c\u65f6\uff0c\u6bcf<\/span>6\u5468\u8054\u5408\u4f7f\u7528<\/span>1mg\/kg<\/span>\u7684<\/span>ipilimumab<\/span>\u6216\u542b\u94c2\u53cc\u836f\u5316\u7597\uff0c\u6b64\u9879\u7814\u7a76\u5c06\u4ee5\u603b\u751f\u5b58\u671f\u4e3a\u4e3b\u8981\u76ee\u6807\uff0c\u8ba1\u5212\u62db\u52df<\/span>1980<\/span>\u4f4d\u75c5\u4eba\u3002<\/span><\/span><\/p>\n

\n
\n
\n
\n

PD-1\u548c\u5176\u5b83\u514d\u75ab\u80bf\u7624\u836f\u7269<\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\u9664\u4e86<\/span>PD-1\/PD-L1\/PD-L2\u548c<\/span>CTLA4-CD80-CD86<\/span>\u9014\u5f84\u5916\uff0c\u7ec6\u80de\u8868\u9762\u7684\u5176\u5b83\u514d\u75ab\u7403\u86cb\u767d\u5bb6\u65cf\u5728\u8c03\u63a7<\/span>T<\/span>\u7ec6\u80de\u5bf9\u6297\u764c\u75c7\u7684\u8fc7\u7a0b\u4e2d\u4e5f\u53d1\u6325\u4e86\u5f88\u5927\u4f5c\u7528\u3002<\/span><\/span><\/p>\n

LAG3\u662f\u4e00\u79cd\u68c0\u67e5\u70b9\u86cb\u767d\uff0c\u5728\u6709\u6297\u539f\u5b58\u5728\u4e0b\uff0c\u5b83\u8c03\u8282<\/span>T<\/span>\u7ec6\u80de\u5bf9<\/span>MHC<\/span>\u2161\u7c7b\u5206\u5b50\u7684\u7ed3\u5408\u3002<\/span>IMP321\uff08<\/span>Immutep<\/span>\u7814\u53d1\uff09\u662f\u4e00\u79cd\u53ef\u6eb6\u89e3\u7684<\/span>LAG3-Fc<\/span>\u878d\u5408\u86cb\u767d\uff0c\u5728\u80be\u764c\u3001\u80f8\u764c\u548c\u80f0\u764c\u7684<\/span>\u2160\u671f\u4e34\u5e8a\u4e2d\u8868\u73b0\u51fa\u4e86\u826f\u597d\u7684\u4f5c\u7528\u6548\u679c\u3002<\/span>BMS-986016\uff08<\/span>BMS<\/span>\u7814\u53d1\uff09\u662f\u4e00\u79cd\u9776\u5411\u4e8e<\/span>LAG3<\/span>\u7684<\/span>IgG4<\/span>\u5355\u514b\u9686\u6297\u4f53\uff0c\u5176\u5728\u6cbb\u7597\u9ed1\u8272\u7d20\u7624\u7684\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u5df2\u7ecf\u53d6\u5f97\u4e86\u4e0d\u9519\u7684\u6548\u679c\u3002\u5728\u8fd9\u4e2a\u8bd5\u9a8c\u4e2d\uff0c\u8fd9\u4e9b\u75c5\u4eba\u6b63\u5728\u6216\u5df2\u7ecf\u63a5\u53d7\u4e86\u8054\u5408<\/span>PD-1\/PD-L1 <\/span>\u548c<\/span>nivolumab<\/span>\u7684<\/span>\u2160\u671f\u4e34\u5e8a\u6cbb\u7597\u3002<\/span><\/span>\u8fd9\u79cd\u836f\u7269\u7684\u4f5c\u7528\u6548\u679c\u826f\u597d\uff0c<\/span>\u75c5\u4eba\u4e2d\u6cbb\u7597\u76f8\u5173\u7684<\/span>3\/4\u7ea7\u526f\u4f5c\u7528\u53d1\u751f\u7387\u4ec5\u4e3a<\/span>9%<\/span>\u3002\u5c3d\u7ba1\u8fd9\u79cd\u836f\u7269\u8054\u5408\u6297<\/span>PD-1\/PD-L1<\/span>\u7684\u5404\u79cd<\/span>\u2160\u671f\u4e34\u5e8a\u7814\u7a76\u6b63\u5728\u8fdb\u884c\uff0c\u4f46\u662f<\/span>IMP321\u548c<\/span>BMS-986016<\/span>\u76ee\u524d\u5747\u6ca1\u6709\u9488\u5bf9<\/span>NSCLC<\/span>\u8fdb\u884c\u4e34\u5e8a\u8bd5\u9a8c\u3002<\/span><\/span><\/span><\/p>\n

\u81ea\u7136\u6740\u4f24\u7ec6\u80de\u8868\u8fbe\u7684\u4e00\u79cd\u8de8\u819c\u7cd6\u86cb\u767d\u6740\u4f24\u6291\u5236\u53d7\u4f53\uff0c\u901a\u8fc7\u8bc6\u522b\u81ea\u8eab<\/span>MHC\u2160\u7c7b\u5206\u5b50\u8c03\u63a7<\/span>NK\u7ec6\u80de\u7684\u6eb6\u89e3\u529f\u80fd\u3002<\/span>Lirilumab<\/span>\u662f\u4e00\u79cd\u9776\u5411\u4e8e\u4e3b\u8981\u6740\u4f24\u6291\u5236\u53d7\u4f53\u7684\u5168\u4eba\u6e90\u5355\u514b\u9686\u6297\u4f53\uff0c\u5728\u5404\u79cd\u6076\u6027\u80bf\u7624\u7684<\/span>\u2160\u671f\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u8868\u73b0\u826f\u597d\uff0c\u51fa\u73b0\u7684\u4e0d\u826f\u53cd\u5e94\u5927\u90fd\u662f\u75b2\u4e4f\uff08<\/span>30%\uff09\u3001\u7619\u75d2\uff08<\/span>20%<\/span>\uff09\u3001\u6ce8\u5c04\u76f8\u5173\u53cd\u5e94\uff08<\/span>14%<\/span>\uff09\u548c\u5934\u75db\uff08<\/span>11%<\/span>\uff09\uff08<\/span>Vey<\/span>\u7b49\uff09\u3002\u8054\u5408\u4f7f\u7528\u8fd9\u79cd\u53d7\u4f53\u4e0e<\/span>nivolumab<\/span>\u7684<\/span>\u2160\/\u2161\u4e34\u5e8a\u8bd5\u9a8c\u7ed3\u679c\u663e\u793a\uff0c\u7ea6\u6709<\/span>25%\u7684\u75c5\u4eba\u75c5\u60c5\u5f97\u5230\u4e86\u5ba2\u89c2\u7f13\u89e3\uff0c\u8fd9\u8bf4\u660e\u4e86\u5176\u5728\u5934\u9888\u90e8\u9cde\u72b6\u7ec6\u80de\u764c\u7684\u6cbb\u7597\u4e2d\u6709\u5de8\u5927\u53d1\u5c55\u524d\u666f\u3002\u8fd9\u79cd\u8054\u5408\u6cbb\u7597\u65b9\u6cd5\u5728\u8840\u6db2\u548c\u9cde\u72b6\u6076\u6027\u80bf\u7624\u7684\u7814\u7a76\u4e5f\u5728\u8fdb\u884c\u4e2d\uff0c\u89c1\u8868<\/span>1<\/span>\u3002<\/span><\/span><\/p>\n

\n
\n
\n
\n

PD-1\u548cIDO\u6291\u5236\u5242<\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

IDO\u662f\u4e00\u79cd\u8272\u6c28\u9178\u5206\u89e3\u4ee3\u8c22\u7684\u50ac\u5316\u5242\uff0c<\/span>Munn<\/span>\u7b49\u8fd1\u671f\u7814\u7a76\u53d1\u73b0\uff0c\u901a\u8fc7\u6291\u5236<\/span>T<\/span>\u7ec6\u80de\u6d3b\u6027\u548c\u5f15\u5bfc\u521d\u59cb<\/span>T<\/span>\u7ec6\u80de\u5206\u5316\uff0c\u80bf\u7624\u7ec6\u80de\u53ef\u4ee5\u4ea7\u751f<\/span>IDO<\/span>\uff0c\u53d1\u751f\u514d\u75ab\u9003\u9038\u3002\u5728\u4e34\u5e8a\u524d\u52a8\u7269\u8bd5\u9a8c\u4e2d\uff0c\u7528<\/span>IDO<\/span>\u6291\u5236\u5242\u6cbb\u7597\uff0c\u63d0\u9ad8\u4e86\u6297\u80bf\u7624\u514d\u75ab\u53cd\u5e94\uff0c\u4e0e\u80bf\u7624\u75ab\u82d7\u548c\u5176\u5b83\u514d\u75ab\u7597\u6cd5\u8054\u7528\u65f6\u80fd\u591f\u534f\u540c\u589e\u6548\u3002<\/span>Soliman<\/span>\u7b49\u7814\u7a76\u53d1\u73b0\uff0c<\/span>Indoximod\u4f5c\u4e3a\u5355\u4e00\u836f\u7269\u5728\u6cbb\u7597\u665a\u671f\u6076\u6027\u5b9e\u4f53\u80bf\u7624\u7684<\/span>\u2160\u671f\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u663e\u793a\u4e86\u826f\u597d\u7684\u836f\u6548\u5b66\u7279\u5f81\uff0c\u65e9\u671f\u54cd\u5e94\u6570\u636e\u663e\u793a\uff0c\u4e00\u4e9b\u75c5\u4eba\u7684\u75be\u75c5\u7a33\u5b9a\u671f\u957f\u4e8e<\/span>6\u4e2a\u6708\u3002<\/span>Beatty<\/span>\u7b49\u7814\u7a76\u53d1\u73b0\uff0c<\/span>Epacadostat<\/span>\u4f5c\u4e3a\u4e00\u79cd\u53e3\u670d<\/span>IDO<\/span>\u6291\u5236\u5242\uff0c\u5728\u8fd1\u671f\u7684<\/span>\u2160\u671f\u4e34\u5e8a\u8bd5\u9a8c\u4e2d\u8868\u73b0\u826f\u597d\u3002\u867d\u7136<\/span><\/span>\u5355\u4e00\u7597\u6cd5\u5e76\u6ca1\u6709\u663e\u793a\u51fa\u5ba2\u89c2\u7f13\u89e3\u7387\uff0c\u4f46\u662f<\/span>52\u4e2a\u75c5\u4eba\u4e2d<\/span>7<\/span>\u4e2a\u75c5\u4eba\u7684<\/span>SD<\/span>\uff08\u75be\u75c5\u7a33\u5b9a\u671f\uff09\u957f\u4e8e<\/span>16<\/span>\u5468\u3002<\/span>E<\/span><\/span>pacadostat\u8054\u5408<\/span>pembrolizumab<\/span>\u4e5f\u88ab\u5e94\u7528\u4e8e\u5f88\u591a\u764c\u75c7\uff08\u5305\u62ec<\/span>NSCLC<\/span>\uff09\u7684\u6cbb\u7597\u7814\u7a76\u3002<\/span>Gangadhar<\/span>\u7b49\u7814\u7a76\u53d1\u73b0\uff0c\u8fd9\u79cd\u7ec4\u5408\u5728<\/span>NSCLC<\/span>\u7684\u603b\u4f53\u5ba2\u89c2\u7f13\u89e3\u7387\u8fbe\u5230<\/span>35%<\/span>\uff0c\u75be\u75c5\u63a7\u5236\u7387\u8fbe\u5230\u4e86<\/span>60%<\/span>\u3002\u8fd9\u79cd\u7ec4\u5408\u6548\u679c\u826f\u597d\uff0c\u526f\u53cd\u5e94\u4e3b\u8981\u662f\u75b2\u4e4f\uff08<\/span>19%<\/span>\uff09\u3001\u5173\u8282\u75db\uff08<\/span>9%<\/span>\uff09\u548c<\/span>AST<\/span>\uff08\u8c37\u8349\u8f6c\u6c28\u9176\uff09\u5347\u9ad8\u3002<\/span><\/span><\/span><\/p>\n

\n
\n
\n
\n

PD-1\u548c\u75ab\u82d7<\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\u75ab\u82d7\u7b56\u7565\u4e5f\u5728\u665a\u671f<\/span>NSCLC\u6cbb\u7597\u4e2d\u7684\u4f7f\u7528\uff0c<\/span><\/span>\u5f88\u591a\u7814\u7a76\u975e\u5e38\u5177\u6709\u524d\u666f\u3002\u5728<\/span>NSCLC\u7684\u4e34\u5e8a\u7814\u7a76\u4e2d\uff0c\u8fd9\u4e9b\u75ab\u82d7\u5bf9\u5176\u4e2d\u4e00\u90e8\u5206\u75c5\u4eba\u6709\u663e\u8457\u7597\u6548\u3002<\/span> <\/span><\/span><\/p>\n

\u5c3d\u7ba1\u8054\u5408\u75ab\u82d7\u7684\u6cbb\u7597\u65b9\u6cd5\u53d6\u5f97\u7684\u8fdb\u6b65\u6709\u9650\uff0c\u4f46\u662f\u5728\u6709\u68c0\u67e5\u70b9\u6291\u5236\u5242\u7684\u73af\u5883\u4e2d\uff0c\u5b83\u5728\u67d0\u4e9b\u75c5\u4eba\u7fa4\u4f53\u4e2d\u7684\u6297\u80bf\u7624\u6d3b\u6027\u4f1a\u63d0\u9ad8\u4e00\u500d\uff0c\u8fd9\u91cd\u65b0\u5524\u8d77\u4e86\u4eba\u4eec\u5bf9\u514d\u75ab\u6cbb\u7597\u9886\u57df\u7684\u5174\u8da3\uff0c\u4e00\u4e9b\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242\u8054\u5408\u75ab\u82d7\u6cbb\u7597\u665a\u671f<\/span>NSCLC\u7684\u4e34\u5e8a\u7814\u7a76\u6b63\u5728\u8fdb\u884c\uff0c\u89c1\u8868<\/span>1<\/span>\u3002<\/span><\/span><\/p>\n

\n
\n
\n
\n

PD-<\/span><\/strong>1<\/span><\/strong>\u548c\u7ec6\u80de\u6cbb\u7597<\/span><\/strong><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\u7ec6\u80de\u6cbb\u7597\uff08<\/span>\u5305\u62ec<\/span>T\u7ec6\u80de\u56de\u8f93\u7ed9\u75c5\u4eba\u4ee5\u6fc0\u8d77\u7279\u5f02\u6027\u80bf\u7624\u514d\u75ab\u5e94\u7b54\u53cd\u5e94\uff09\u63d0\u4f9b\u4e86\u4e00\u79cd\u6f5c\u5728\u7684\u514d\u75ab\u6cbb\u7597\u65b9\u6cd5\u3002\u7ec6\u80de\u7597\u6cd5\u7684\u4e34\u5e8a\u7814\u7a76\u65e9\u4e8e\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242\uff0c\u4e3a\u63d0\u9ad8\u7ec6\u80de\u7597\u6cd5\u7684\u4f5c\u7528\u6548\u679c\uff0c\u8fd1\u671f\u7814\u7a76\u7684\u91cd\u70b9\u5728\u4e8e\u8054\u5408\u8fd9\u4e9b\u6cbb\u7597\u65b9\u6cd5\uff0c\u907f\u514d\u6291\u5236\u56e0\u5b50\u9650\u5236\u7ec6\u80de\u7597\u6cd5\u7684\u4f5c\u7528\u3002<\/span><\/span><\/span><\/p>\n

\u5728<\/span>TIL\uff08\u80bf\u7624\u6d78\u6da6\u6dcb\u5df4\u7ec6\u80de\uff09\u6cbb\u7597\u4e2d\u52a0\u5165\u68c0\u67e5\u70b9\u6291\u5236\u5242\u4ee5\u6cbb\u7597\u9ed1\u8272\u7d20\u7624\u7684\u4e34\u5e8a\u8bd5\u9a8c\u6b63\u5728\u8fdb\u884c\uff0c\u5176\u4e2d\u81f3\u5c11\u4e00\u9879\u8ba1\u5212\u7528\u4e8e<\/span>NSCLC<\/span>\uff0c\u89c1\u8868<\/span>1<\/span>\u3002<\/span><\/span><\/p>\n

\u5229\u7528\u80bf\u7624\u6297\u539f\u7279\u5f02\u6027\u7684\u5de5\u7a0b<\/span>T\u7ec6\u80de\u6216\u878d\u5408\u6297\u539f\u53d7\u4f53\u7684\u6cbb\u7597\u65b9\u6cd5\u5728\u8840\u6db2\u6076\u6027\u80bf\u7624\uff08\u5305\u62ec\u6025\u6027\u6dcb\u5df4\u7ec6\u80de\u767d\u8840\u75c5\uff09\u7684\u6cbb\u7597\u4e0a\u53d6\u5f97\u4e86\u5de8\u5927\u7684\u6210\u529f\u3002\u5de5\u7a0b<\/span>T<\/span>\u7ec6\u80de\u5bf9\u4e0d\u540c\u6297\u539f\u6709\u4e0d\u540c\u7684\u7279\u5f02\u6027\uff0c\u8fd9\u79cd\u7279\u5f02\u6027\u7684<\/span>\u2160\u671f\u4e34\u5e8a\u8bd5\u9a8c\u6b63\u5728\u5404\u79cd\u5b9e\u4f53\u7624\uff08\u5305\u62ec<\/span>NSCLC\uff09\u4e2d\u8fdb\u884c<\/span><\/span>\uff0c\u76ee\u524d\u8fd8\u6ca1\u6709\u627e\u5230\u4e00\u79cd\u6709\u6548\u7684\u7ed3\u5408\u68c0\u67e5\u70b9\u6291\u5236\u5242\u7684\u65b9\u6cd5\u3002<\/span><\/span><\/p>\n

\n
\n
\n
\n

PD-1\u548c\u8868\u89c2\u8c03\u63a7\u56e0\u5b50<\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\u5728\u764c\u75c7\u548c\u514d\u75ab\u7cfb\u7edf\u4e4b\u95f4\u53d1\u6325\u91cd\u8981\u4f5c\u7528\u7684\u8868\u89c2\u9057\u4f20\u4fee\u9970\u56e0\u5b50\u6b63\u65e5\u76ca\u5f15\u8d77\u91cd\u89c6\u3002<\/span>DNA\u7532\u57fa\u5316\u3001\u7ec4\u86cb\u767d\u4fee\u9970\u7b49\u673a\u80fd\u5f71\u54cd\u514d\u75ab\u68c0\u67e5\u70b9\u548c\u80bf\u7624\u6297\u539f\u8868\u8fbe\uff0c\u8d8a\u6765\u8d8a\u591a\u7684\u8bc1\u636e\u8868\u660e\uff0c\u8054\u5408\u8868\u89c2\u9057\u4f20\u8c03\u63a7\u7684\u6cbb\u7597\u65b9\u6cd5\u5c06\u4f1a\u6539\u53d8\u6216\u6709\u6548\u63d0\u9ad8\u514d\u75ab\u6cbb\u7597\u7684\u6548\u679c\u3002<\/span><\/span><\/p>\n

\u7ec4\u86cb\u767d\u8131\u4e59\u9170\u57fa\u9176\uff08<\/span>HDAC\uff09\u6291\u5236\u5242\u5df2\u7ecf\u8bc1\u660e\u5728\u6cbb\u7597\u8840\u6db2\u6076\u6027\u80bf\u7624\u4e2d\u53d1\u6325\u91cd\u8981\u4f5c\u7528\uff0c\u8fd1\u6765\u7814\u7a76\u53d1\u73b0\uff0c\u8fd9\u79cd\u6291\u5236\u5242\u53ef\u4ee5\u901a\u8fc7\u6291\u5236\u7ec6\u80de\u589e\u6b96\u53d1\u6325\u514d\u75ab\u539f\u6548\u7528\u3002\u5c24\u5176\u503c\u5f97\u6ce8\u610f\u7684\u662f\uff0c<\/span>Zheng<\/span>\u7b49\u7814\u7a76\u53d1\u73b0\uff0c<\/span>HDAC<\/span>\u6291\u5236\u5242\u80fd\u591f\u63d0\u9ad8\u80bf\u7624\u7ec6\u80de\u4e2d\u4e0d\u540c<\/span>T<\/span>\u7ec6\u80de\u5316\u5b66\u589e\u6d3b\u7d20\u7684\u8868\u8fbe\u3002\u5728\u4e0d\u540c\u7684\u80ba\u764c\u6a21\u578b\u7814\u7a76\u4e2d\uff0c\u5f53\u8054\u5408<\/span>HDAC<\/span>\u6291\u5236\u5242\u4f7f\u7528\u65f6\uff0c\u7531<\/span>PD-1<\/span>\u6291\u5236\u4f5c\u7528\u800c\u4ea7\u751f\u7684\u6297\u80bf\u7624<\/span>T<\/span>\u7ec6\u80de\u54cd\u5e94\u7387\u660e\u663e\u63d0\u9ad8\u3002\u5176\u5b83\u6b63\u5728\u8fdb\u884c\u7684\u4e34\u5e8a\u8bd5\u9a8c\u89c1\u8868<\/span>1<\/span>\u3002<\/span><\/span><\/p>\n

\n
\n
\n
\n

PD-1\u548cVEGF<\/span><\/p>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

VEGF\u53ef\u4ee5\u652f\u6301\u7ec4\u7ec7\u91cd\u5851\u6216\u7ea4\u7ef4\u5316\uff0c\u4e5f\u53ef\u4ee5\u963b\u6b62\u514d\u75ab\u7ec6\u80de\u6e17\u900f\u5230\u80bf\u7624\uff0c\u4ece\u800c\u6291\u5236\u514d\u75ab\u4f5c\u7528\u3002<\/span><\/span>\u8fd9\u6837\uff0c\u6291\u5236<\/span>VEGF\u4f5c\u7528\u800c\u63d0\u9ad8\u6297\u80bf\u7624\u514d\u75ab\u6548\u7528\u7684\u65b9\u6cd5\u5e94\u8fd0\u800c\u751f\u3002\u8fd1\u671f<\/span>Hodi<\/span>\u7814\u7a76\u53d1\u73b0\uff0c<\/span>bewacizumab<\/span>\u548c<\/span>ipilimumab<\/span>\u8054\u5408\u6cbb\u7597\u7684\u6548\u679c\u8f83\u597d\uff0c\u75be\u75c5\u63a7\u5236\u7387\u8fbe\u5230<\/span>67.4%<\/span>\uff0c\u76f8\u5173\u5206\u6790\u663e\u793a\u4e86\u514d\u75ab\u4f5c\u7528\u7684\u63d0\u9ad8\u548c\u6dcb\u5df4\u7ec6\u80de\u7684\u6709\u6548\u8f6c\u79fb\u3002\u9776\u5411<\/span>VEGF<\/span>\u6216<\/span>VEGFR<\/span>\u7684\u836f\u7269\uff08\u5305\u62ec<\/span>bewacizumab<\/span>\u548c<\/span>ipilimumab<\/span>\uff09\u5df2\u7ecf\u5e94\u7528\u5728<\/span>NSCLC<\/span>\u7684\u6cbb\u7597\u4e2d\u3002\u5c3d\u7ba1\u8fd9\u79cd\u7597\u6cd5\u4ecd\u5728\u7814\u7a76\u4e2d\uff0c\u4f46\u662f\u5176\u5e94\u7528\u524d\u666f\u975e\u5e38\u5149\u660e\u3002\u5176\u5b83\u7684\u4e34\u5e8a\u7814\u7a76\u89c1\u8868<\/span>1<\/span>\u3002<\/span><\/span><\/span><\/p>\n

\u8868<\/span>1 \u90e8\u5206\u514d\u75ab\u68c0\u67e5\u70b9\u6291\u5236\u5242\u548c<\/span>\/\u6216\u65b0\u514d\u75ab\u6cbb\u7597\u65b9\u6cd5\u7684\u4e34\u5e8a\u7814\u7a76\u4e00\u89c8<\/span><\/span><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

\u9776\u6807<\/span><\/p>\n<\/td>\n

\n

\u7814\u7a76\u5185\u5bb9<\/span><\/p>\n<\/td>\n

\n

\u4e34\u5e8a<\/span><\/p>\n<\/td>\n

\n

\u5728\u7814\u836f\u7269<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

LAG-3<\/span><\/p>\n<\/td>\n

\n

\u6709\/<\/span>\u65e0\u6297<\/span>PD-l<\/span>\u548c\u6297<\/span>LAG-3<\/span>\u5728\u6cbb\u7597\u5b9e\u4f53\u7624\u4e2d\u7684\u5b89\u5168\u6027\u7814\u7a76<\/span><\/span><\/p>\n<\/td>\n

\n

\u2160<\/span><\/p>\n<\/td>\n

\n

BMS-986016<\/span><\/p>\n

Nivolumab<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

\u665a\u671fNSCLC<\/span>\u7684\u68c0\u6d4b\u548c\u6cbb\u7597\u6548\u679c\u7684\u7814\u7a76<\/span><\/span><\/p>\n<\/td>\n

\n

\u2161<\/span><\/p>\n<\/td>\n

\n

BMS-986016<\/span><\/p>\n

Nivolumab<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

LAG525\u836f\u7269\u5355\u72ec\u548c\u8054\u5408<\/span>PDR001<\/span>\u5728\u665a\u671f\u6076\u6027\u80bf\u7624\u4e2d\u7684\u7814\u7a76<\/span><\/span><\/p>\n<\/td>\n

\n

\u2160\/\u2161<\/span><\/p>\n<\/td>\n

\n

LAG525<\/span><\/p>\n

PDR001\uff08\u6297<\/span>PD-1<\/span>\uff09<\/span><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

TIM-3<\/span><\/p>\n<\/td>\n

\n

\u6297TIM-3<\/span>\u5355\u514b\u9686\u6297\u4f53\u5728\u665a\u671f\u5b9e\u4f53\u7624\u4e2d\u7684\u7814\u7a76<\/span><\/span><\/p>\n<\/td>\n

\n

\u2160<\/span><\/p>\n<\/td>\n

\n

TSR-022<\/span><\/p>\n

\u6297PD-1<\/span>\u6297\u4f53<\/span><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

LY3321367\u5355\u72ec\u6216\u8054\u5408<\/span>LY3300054<\/span>\u5728\u665a\u671f\u590d\u53d1<\/span>\/<\/span>\u96be\u6cbb\u6027\u5b9e\u4f53\u7624\u7684\u7814\u7a76<\/span><\/span><\/p>\n<\/td>\n

\n

\u2160<\/span><\/p>\n<\/td>\n

\n

LY3321367\uff08\u6297<\/span>TIM-3<\/span>\uff09<\/span><\/span><\/p>\n

LY3300054\uff08\u6297<\/span>PD-L1<\/span>\uff09<\/span><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

MBG453\u5355\u72ec\u548c\u8054\u5408<\/span>PDR001<\/span>\u5728\u665a\u671f\u6076\u6027\u80bf\u7624\u4e2d\u7684\u7814\u7a76<\/span><\/span><\/p>\n<\/td>\n

\n

\u2160\/\u2161<\/span><\/p>\n<\/td>\n

\n

MBG453\uff08\u6297<\/span>TIM-3<\/span>\uff09<\/span><\/span><\/p>\n

PDR001\uff08\u6297<\/span>PD-1<\/span>\uff09<\/span><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

B7-H3<\/span><\/p>\n<\/td>\n

\n

Enoblituzumab\u8054\u5408<\/span>ipilimumab<\/span>\u5728\u96be\u6cbb\u6027\u764c\u75c7\u4e2d\u7684\u7814\u7a76<\/span><\/span><\/p>\n<\/td>\n

\n

\u2160<\/span><\/p>\n<\/td>\n

\n

Enoblituzumab<\/span><\/p>\n

ipilimumab<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Enoblituzumab\u8054\u5408<\/span>pembrolizumab<\/span>\u5728\u590d\u53d1\u6027\u764c\u75c7\u4e2d\u7684\u7814\u7a76<\/span><\/span><\/p>\n<\/td>\n

\n

\u2160<\/span><\/p>\n<\/td>\n

\n

Enoblituzumab<\/span><\/p>\n

pembrolizumab<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

OX40<\/span><\/p>\n<\/td>\n

\n

Avelumab\u8054\u5408\u5176\u5b83\u764c\u75c7\u514d\u75ab\u7597\u6cd5\u5728\u665a\u671f\u6076\u6027\u80bf\u7624\u4e2d\u7684\u7814\u7a76<\/span><\/span><\/p>\n<\/td>\n

\n

\u2161<\/span><\/p>\n<\/td>\n

\n

PF-04518600\uff08\u6297<\/span>OX40<\/span>\uff09<\/span><\/span><\/p>\n

Utomilumab<\/span><\/p>\n

Avelumab<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

OX40\u5174\u594b\u5242<\/span>PF-04518600<\/span>\u5355\u72ec\u6216\u8054\u5408<\/span>4-1BB<\/span>\u5174\u594b\u5242<\/span>PF-05082566<\/span><\/span><\/p>\n<\/td>\n

\n

\u2160<\/span><\/p>\n<\/td>\n

\n

PF-04518600<\/span><\/p>\n

PF-05082566<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

MOXR0916\u548c<\/span>atezolizumab<\/span>\u5728\u665a\u671f\u6216\u6076\u6027\u5b9e\u4f53\u7624\u4e2d\u7684\u7814\u7a76<\/span><\/span><\/p>\n<\/td>\n

\n

\u2160<\/span><\/p>\n<\/td>\n

\n

MOXR0916<\/span><\/p>\n

atezolizumab<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

INCAGN1949\u8054\u5408\u514d\u75ab\u7597\u6cd5\u5728\u665a\u671f\u6216\u6076\u6027\u80bf\u7624\u4e2d\u7684\u7814\u7a76<\/span><\/span><\/p>\n<\/td>\n

\n

\u2160<\/span><\/p>\n<\/td>\n

\n

INCAGN1949<\/span><\/p>\n

Nivolumab<\/span><\/p>\n

Ipilimumab<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

MED16383\u5355\u72ec\u548c\u8054\u5408<\/span>MED14736<\/span>\u5728\u6210\u4eba\u665a\u671f\u5b9e\u4f53\u7624\u4e2d\u7684\u7814\u7a76<\/span><\/span><\/p>\n<\/td>\n

\n

\u2160<\/span><\/p>\n<\/td>\n

\n

MED16383\uff08\u6297<\/span>OX40<\/span>\uff09<\/span><\/span><\/p>\n

MED14736\uff08<\/span>durvalumab<\/span>\uff09<\/span><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

CD27<\/span><\/p>\n<\/td>\n

\n

\u6297CD27<\/span>\uff08<\/span>varlilumab<\/span>\uff09\u548c\u6297<\/span>PD-1<\/span>\uff08<\/span>nivolumab<\/span>\uff09\u5728\u665a\u671f\u96be\u6cbb\u6027\u5b9e\u4f53\u7624\u4e2d\u7684\u7814\u7a76<\/span><\/span><\/p>\n<\/td>\n

\n

\u2160\/\u2161<\/span><\/p>\n<\/td>\n

\n

Varlilumab<\/span><\/p>\n

nivolumab<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

4-1BB<\/span><\/p>\n<\/td>\n

\n

Urelumab\u8054\u5408<\/span>nivolumab<\/span>\u5728\u5b9e\u4f53\u7624\u548c\u975e\u970d\u5947\u91d1\u6dcb\u5df4\u7624\u4e2d\u7684\u7814\u7a76<\/span><\/span><\/p>\n<\/td>\n

\n

\u2160\/\u2161<\/span><\/p>\n<\/td>\n

\n

Urelumab<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Avelumab\u8054\u5408\u5176\u5b83\u764c\u75c7\u514d\u75ab\u7597\u6cd5\u5728\u665a\u671f\u6076\u6027\u80bf\u7624\u4e2d\u7684\u7814\u7a76<\/span><\/span><\/p>\n<\/td>\n

\n

\u2161<\/span><\/p>\n<\/td>\n

\n

Utomilumab PF-04518600\uff08\u6297<\/span>OX40<\/span>\uff09<\/span><\/span><\/p>\n

Avelumab<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

OX40\u5174\u594b\u5242<\/span>PF-04518600<\/span>\u5355\u72ec\u548c\u8054\u5408<\/span>4-1BB<\/span>\u5174\u594b\u5242<\/span>PF-05082566<\/span>\uff08<\/span>utomilumab<\/span>\uff09<\/span><\/span><\/p>\n<\/td>\n

\n

\u2160<\/span><\/p>\n<\/td>\n

\n

PF-04518600<\/span><\/p>\n

PF-05082566<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

IDO<\/span><\/p>\n<\/td>\n

\n

Pembrolizumab\u8054\u5408<\/span>epacadostat<\/span>\u7528\u4e8e\u764c\u75c7\u7684\u7814\u7a76\uff08<\/span>ECHO-202<\/span>\uff09<\/span><\/span><\/p>\n<\/td>\n

\n

\u2160\/\u2161<\/span><\/p>\n<\/td>\n

\n

Epacadostat<\/span><\/p>\n

Pembrolizuma<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Epacadostat\uff08<\/span>INCB024360<\/span>\uff09\u8054\u5408<\/span>durvalumab<\/span>\u5728\u665a\u671f\u5b9e\u4f53\u7624\u7684\u7814\u7a76\uff08<\/span>ECHO-203<\/span>\uff09<\/span><\/span><\/p>\n<\/td>\n

\n

\u2160\/\u2161<\/span><\/p>\n<\/td>\n

\n

Epacadostat<\/span><\/p>\n

MED14736\uff08<\/span>durvalumab<\/span>\uff09<\/span><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Epacadostat\u8054\u5408<\/span>nivolumab<\/span>\u5728\u665a\u671f\u764c\u75c7\u7684\u7814\u7a76\uff08<\/span>ECHO-204<\/span>\uff09<\/span><\/span><\/p>\n<\/td>\n

\n

\u2160\/\u2161<\/span><\/p>\n<\/td>\n

\n

Epacadostat<\/span><\/p>\n

nivolumab<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Azatitidine\u8054\u5408<\/span>pembrolizumab<\/span>\u548c<\/span>epacadostat<\/span>\u5728\u665a\u671f\u5b9e\u4f53\u7624\u7684\u7814\u7a76\uff08<\/span>ECHO-206<\/span>\uff09<\/span><\/span><\/p>\n<\/td>\n

\n

\u2160\/\u2161<\/span><\/p>\n<\/td>\n

\n

Epacadostat<\/span><\/p>\n

Pembrolizumab<\/span><\/p>\n

Azatitidine<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Epacadostat\u8054\u5408<\/span>PD-1<\/span>\u6291\u5236\u5242\u548c\u5316\u7597\u5728\u665a\u671f\u6216\u6269\u6563\u6027\u5b9e\u4f53\u7624\u7684\u7814\u7a76\uff08<\/span>ECHO-207<\/span>\uff09<\/span><\/span><\/p>\n<\/td>\n

\n

\u2160\/\u2161<\/span><\/p>\n<\/td>\n

\n

Epacadostat<\/span><\/p>\n

Nivolumab\u6216<\/span><\/span><\/p>\n

Pembrolizumab<\/span><\/p>\n

\u5316\u7597<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

BMS-986205\u8054\u5408<\/span>nivolumab<\/span>\u6216\u8054\u5408<\/span>nivolumab<\/span>\u548c<\/span>ipilimumab<\/span>\u5728\u665a\u671f\u6216\u6269\u6563\u6027\u764c\u75c7\u4e2d\u7684\u7814\u7a76<\/span><\/span><\/p>\n<\/td>\n

\n

\u2160\/\u2161<\/span><\/p>\n<\/td>\n

\n

BMS-986205<\/span><\/p>\n

Nivolumab<\/span><\/p>\n

ipilimumab<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

TGF-\u03b2<\/span><\/p>\n<\/td>\n

\n

Galunisertib\u8054\u5408<\/span>nivolumab<\/span>\u5728\u665a\u671f\u96be\u6cbb\u6027\u5b9e\u4f53\u7624\u7684\u7814\u7a76<\/span><\/span><\/p>\n<\/td>\n

\n

\u2160\/\u2161<\/span><\/p>\n<\/td>\n

\n

Galunisertib\uff08\u6297<\/span>TGF-<\/span>\u03b2\uff09<\/span><\/p>\n

nivolumab<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Daratumumab<\/span><\/p>\n<\/td>\n

\n

Nivolumab\u8054\u5408<\/span>Daratumumab\u5728\u665a\u671f\u6216\u6269\u6563\u6027\u5b9e\u4f53\u7624\u7684\u7814\u7a76<\/span><\/span><\/p>\n<\/td>\n

\n

\u2160\/\u2161<\/span><\/p>\n<\/td>\n

\n

Daratumumab<\/span><\/p>\n

Nivoluma<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

PD-1+\u75ab\u82d7<\/span><\/span><\/p>\n<\/td>\n

\n

NEO-PV-01+\u4f50\u5242\u8054\u5408<\/span>nivolumab<\/span>\u5728\u6cbb\u7597\u9ed1\u8272\u7d20\u7624\u3001<\/span>NSCLC<\/span>\u6216\u8180\u80f1\u79fb\u884c\u7ec6\u80de\u764c\u7684\u7814\u7a76<\/span><\/span><\/p>\n<\/td>\n

\n

\u2160<\/span><\/p>\n<\/td>\n

\n

NEO-PV-01<\/span><\/p>\n

\u75ab\u82d7\u6297\u4f53\u4f50\u5242<\/span><\/p>\n

\u5316\u7597<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

\u6cbb\u7597\u6027\u809d\u764c\u75ab\u82d7\uff08HS-110<\/span>\uff09\u8054\u5408\u591a\u79cd\u6cbb\u7597\u65b9\u6cd5\u5728<\/span>NSCLC<\/span>\u7684\u7814\u7a76<\/span><\/span><\/p>\n<\/td>\n

\n

\u2160\/\u2161<\/span><\/p>\n<\/td>\n

\n

\u6cbb\u7597\u6027\u809d\u764c\u75ab\u82d7<\/span><\/p>\n

nivolumab<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

EGF\u75ab\u82d7<\/span>CIMAvax<\/span>\u8054\u5408\u6297<\/span>PD-1nivolumab<\/span>\u5728\u6cbb\u7597\u8fc7\u7684\u665a\u671f<\/span>NSCLC<\/span>\u7684\u7814\u7a76<\/span><\/span><\/p>\n<\/td>\n

\n

\u2160\/\u2161<\/span><\/p>\n<\/td>\n

\n

Nivolumab<\/span><\/p>\n

\u91cd\u7ec4\u4ebaEGF-rP64K<\/span><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

\u514d\u75ab\u7597\u6cd5\u8054\u5408mRNA<\/span>\u75ab\u82d7\u5728<\/span>NSCLC1\/2<\/span>\u671f\u7814\u7a76<\/span><\/span><\/p>\n<\/td>\n

\n

\u2160\/\u2161<\/span><\/p>\n<\/td>\n

\n

Durvalumab\uff0c<\/span>tremelimumab<\/span><\/span><\/p>\n

BI1361849\uff08<\/span>mRNA<\/span>\u75ab\u82d7\uff09<\/span><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

ACT<\/span><\/p>\n<\/td>\n

\n

Nivolumab\u548c\u80bf\u7624\u6e17\u900f\u6dcb\u5df4\u7ec6\u80de\uff08<\/span>TIL<\/span>\uff09\u5728\u665a\u671f<\/span>NSCLC<\/span>\u7684\u7814\u7a76<\/span><\/span><\/p>\n<\/td>\n

\n

\u2160<\/span><\/p>\n<\/td>\n

\n

TIL<\/span><\/p>\n

Nivolumab<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

\u57fa\u56e0\u4fee\u9970T<\/span>\u7ec6\u80de\u3001\u75ab\u82d7\u6cbb\u7597\u548c<\/span>ipilimumab<\/span>\u5728\u6cbb\u7597\u665a\u671f\u6216\u6269\u6563\u6027\u6076\u6027\u80bf\u7624\u7684\u7814\u7a76<\/span><\/span><\/p>\n<\/td>\n

\n

\u2160<\/span><\/p>\n<\/td>\n

\n

\u6811\u7a81\u7ec6\u80de<\/span><\/p>\n

\u75ab\u82d7\u6cbb\u7597<\/span><\/p>\n

Ipilimumab<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

VEGF<\/span><\/p>\n<\/td>\n

\n

Ramucirumab+pembrolizumab\u5728<\/span>NSCLC<\/span>\u3001\u8180\u80f1\u8f6c\u79fb\u6027\u7ec6\u80de\u764c\u548c\u80c6\u7ba1\u764c\u7684\u7814\u7a76<\/span><\/span><\/p>\n<\/td>\n

\n

\u2160<\/span><\/p>\n<\/td>\n

\n

Ramucirumab<\/span><\/p>\n

pembrolizumab<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Ramucirumab\uff08<\/span>LY3009806<\/span>\uff09<\/span>+MED14736<\/span>\u5728\u665a\u671f\u80c3\u80a0\u6216\u80f8\u90e8\u6076\u6027\u80bf\u7624\u7684\u7814\u7a76<\/span><\/span><\/p>\n<\/td>\n

\n

\u2160<\/span><\/p>\n<\/td>\n

\n

Ramucirumab<\/span><\/p>\n

MED14736\uff08<\/span>durvalumab<\/span>\uff09<\/span><\/span><\/p>\n<\/td>\n<\/tr>\n

\n

HDAC\u6291\u5236\u5242<\/span><\/span><\/p>\n<\/td>\n

\n

HDAC\u6291\u5236\u5242<\/span>mocetinostat<\/span>\u8054\u5408<\/span>PD-L1<\/span>\u6291\u5236\u5242<\/span>durvalumab<\/span>\uff0c\u5728\u665a\u671f\u6216\u6269\u6563\u6027\u5b9e\u4f53\u7624\u548c<\/span>NSCLC<\/span>\u7684\u7814\u7a76<\/span><\/span><\/p>\n<\/td>\n

\n

\u2160\/\u2161<\/span><\/p>\n<\/td>\n

\n

Mocetinostat<\/span><\/p>\n

durvalumab<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Entinostat\u8054\u5408<\/span>pembrolizumab<\/span>\u5728<\/span>NSCLC<\/span>\u7684\u7814\u7a76<\/span><\/span><\/p>\n<\/td>\n

\n

\u2160\/\u2161<\/span><\/p>\n<\/td>\n

\n

Entinostat<\/span><\/p>\n

pembrolizumab<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

Pembrolizumab\u548c<\/span>vorinostat<\/span>\u5728<\/span>NSCLC<\/span>\u7684\u7814\u7a76<\/span><\/span><\/p>\n<\/td>\n

\n

\u2160\/\u2161<\/span><\/p>\n<\/td>\n

\n

Vorinostat<\/span><\/p>\n

Pembrolizumab<\/span><\/p>\n<\/td>\n<\/tr>\n

\n

\u5e73\u884c2<\/span>\u671f<\/span>Glesatinib\u3001<\/span>sitravatinib<\/span>\u6216<\/span>mocetinostat<\/span>\u8054\u5408<\/span>nivolumab<\/span>\u5728\u665a\u671f\u6216\u6269\u6563\u6027<\/span>NSCLC<\/span>\u7684\u7814\u7a76<\/span><\/span><\/p>\n<\/td>\n

\n

\u2161<\/span><\/p>\n<\/td>\n

\n

Mocetinostat<\/span><\/p>\n

nivolumab<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u53c2\u8003\u6587\u732e<\/span><\/strong>
<\/p>\n

1.<\/span>Gubens MA, Sequist LV, Stevenson J, et al. Phase I\/II study of pembrolizumab (pembro) plus ipilimumab (ipi) as second-line therapy for NSCLC: KEYNOTE-021 cohorts D and H. J Clin Oncol 2016;34:9027. <\/span><\/span><\/p>\n

2.<\/span> Antonia S, Goldberg SB, Balmanoukian A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol 2016;17:299-308. <\/span><\/span><\/p>\n

3.<\/span> Hellmann MD, Rizvi NA, Goldman JW, et al. Nivolumab plus ipilimumab as first-line treatment for advanced nonsmall-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol 2017;18:31-41.<\/span><\/span><\/p>\n

4. Vey N, Goncalves A, Karlin L, et al. A phase 1 doseescalation study of IPH2102 (lirilumab, BMS-986015, LIRI), a fully human anti KIR monoclonal antibody (mAb) in patients (pts) with various hematologic (HEM) or solid malignancies (SOL). J Clin Oncol 2015;33:3065.<\/span><\/p>\n

5. Munn DH. Blocking IDO activity to enhance anti-tumor immunity. Front Biosci (Elite Ed) 2012;4:734-45. <\/span><\/p>\n

6.<\/span> Soliman HH, Minton SE, Han HS, et al. A phase I study of indoximod in patients with advanced malignancies. Oncotarget 2016;7:22928-38. <\/span><\/span><\/p>\n

7.<\/span> Beatty GL, O’Dwyer PJ, Clark J, et al. First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies. Clin Cancer Res 2017;23:3269-76.<\/span><\/span><\/p>\n

8.<\/span> Gangadhar TC, Schneider BJ, Bauer TM, et al. Efficacy and safety of epacadostat plus pembrolizumab treatment of NSCLC: Preliminary phase I\/II results of ECHO-202\/ KEYNOTE-037. J Clin Oncol 2017;35:9014.<\/span><\/span><\/p>\n

9.<\/span> Zheng H, Zhao W, Yan C, et al. HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma. Clin Cancer Res 2016;22:4119-32.<\/span><\/span><\/p>\n

10.<\/span> Hodi FS, Lawrence D, Lezcano C, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2014;2:632-42.<\/span><\/span><\/p>\n

\u8bc6\u522b\u5fae\u4fe1\u4e8c\u7ef4\u7801\uff0c\u6dfb\u52a0\u751f\u7269\u5236\u54c1\u5708\u5c0f\u7f16\uff0c\u7b26\u5408\u6761\u4ef6\u8005\u5373\u53ef\u52a0\u5165\u751f\u7269\u5236\u54c1\u5fae\u4fe1\u7fa4\uff01<\/strong>
<\/p>\n


<\/p>\n

\n
\n

\u8bf7\u6ce8\u660e\uff1a\u59d3\u540d+\u7814\u7a76\u65b9\u5411\uff01<\/strong><\/span><\/p>\n

\"\u514d\u75ab\u68c0\u67e5\u70b9\u7684\u6545\u4e8b|PD-1\u514d\u75ab\u8054\u5408\u7597\u6cd5\u5728NSCLC\u4e2d\u7684\u7814\u7a76\u8fdb\u5c55\"<\/p>\n

\n
\n
\n

<\/section>\n<\/section>\n<\/section>\n<\/section>\n
\n
\n
\n
<\/section>\n
<\/section>\n<\/section>\n
\n
\n
<\/span><\/strong><\/span>\u7248<\/section>\n<\/section>\n
\n
\u6743<\/section>\n<\/section>\n
\n
\u58f0<\/section>\n<\/section>\n
\n
\u660e<\/section>\n<\/section>\n<\/section>\n<\/section>\n<\/section>\n

\u7248\u6743\u4e3a\u751f\u7269\u5236\u54c1\u5708\u6240\u6709\u3002\u6b22\u8fce\u4e2a\u4eba\u8f6c\u53d1\u5206\u4eab\u3002\u5176\u4ed6\u4efb\u4f55\u5a92\u4f53\u3001\u7f51\u7ad9\u5982\u9700\u8f6c\u8f7d\u6216\u5f15\u7528\u672c\u7f51\u7248\u6743\u6240\u6709\u5185\u5bb9\u987b\u83b7\u5f97\u6388\u6743\u4e14\u5728\u9192\u76ee\u4f4d\u7f6e\u5904\u6ce8\u660e\u201c\u8f6c\u81ea\uff1a\u751f\u7269\u5236\u54c1\u5708\u201d\u3002\"\u514d\u75ab\u68c0\u67e5\u70b9\u7684\u6545\u4e8b|PD-1\u514d\u75ab\u8054\u5408\u7597\u6cd5\u5728NSCLC\u4e2d\u7684\u7814\u7a76\u8fdb\u5c55\"<\/span><\/p>\n<\/section>\n<\/section>\n

\n

\u59cb\u53d1\u4e8e\u5fae\u4fe1\u516c\u4f17\u53f7\uff1a \u751f\u7269\u5236\u54c1\u5708 <\/p>\n<\/blockquote>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

\u514d\u75ab\u68c0\u67e5\u70b9\u662f\u6307\u514d\u75ab\u7cfb\u7edf\u4e2d\u5b58\u5728\u7684\u4e00\u4e9b\u6291\u5236\u6027\u4fe1\u53f7\u901a\u8def\u3002\u673a\u4f53\u5728\u6b63\u5e38\u60c5\u51b5\u4e0b\uff0c\u514d\u75ab\u68c0\u67e5\u70b9\u53ef\u4ee5\u901a\u8fc7\u8c03\u8282\u81ea\u8eab\u514d\u75ab\u53cd\u5e94\u7684\u5f3a\u5ea6\u6765 […]<\/p>\n","protected":false},"author":1,"featured_media":25520,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[2],"tags":[],"_links":{"self":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/25519"}],"collection":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/comments?post=25519"}],"version-history":[{"count":1,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/25519\/revisions"}],"predecessor-version":[{"id":25527,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/25519\/revisions\/25527"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media\/25520"}],"wp:attachment":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media?parent=25519"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/categories?post=25519"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/tags?post=25519"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}